Effects of tirofiban on no-reflow in patients with acute ST-elevation myocardial infarction admitted between 6 and 12 hours of symptom onset undergoing primary percutaneous coronary intervention

Objective:To evaluate the effects of tirofiban therapy on no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction(STEMI) admitted from 6 to 12 hours of symptom onset undergoing primary percutaneous coronary intervention(PCI).Methods:One hundred patients with acute STEMI eligible to the study were randomly allocated to tirofiban group(n=50) and control group(n=50).Clinical characteristics,no-reflow rates,heart failure,major adverse cardiac events(MACE) during hospitalization and 180-day follow-up were compared.Results:Compared with control group,the incidence of TIMI grade 3 flow before PCI and TMP Grade 3 after PCI were significantly increased in tirofiban group.TIMI grade 3 flow after PCI was similar in the two groups.The incidence of no-reflow(includes TIMI grade 0—2 flow and TMP grade 0—2 after PCI) was decreased by 22.9%(P0.05) and heart failure during hospitalization was decreased by 27.4%.At 180-days follow-up,the rate of MACE was decreased by 10.85%(P0.05).Conclusion:Combined therapy of tirofiban with primary PCI reduced the occurrence rate of no-reflow,and improved myocardial reperfusion,cardiac function and clinical outcomes.